Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Bolodeoku, J."'
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 29
There are a number of hand-held cholesterol testing devices such as the CardioChek, Mission, 3in1 available. These devices measure a range of lipid fractions such as the Total Cholesterol...
Publikováno v:
In Atherosclerosis August 2023 379 Supplement 1:S65-S65
Publikováno v:
International Journal of Medical Research and Health Sciences, Vol 6, Iss 5, Pp 76-81 (2017)
Laboratory analytical turnaround time is a well-recognised indicator of how well a laboratory is performing and is sometimes regarded as the benchmark for laboratory performance. Methods: Total 104 doctors in public and private health institutions in
Autor:
Chapple, C.R. *, Martinez-Garcia, R., Selvaggi, L., Toozs-Hobson, P., Warnack, W., Drogendijk, T., Wright, D.M., Bolodeoku, J.
Publikováno v:
In European Urology 2005 48(3):464-470
Autor:
Bolodeoku J
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 23
Point of Care Testing (POCT) in the monitoring of hypertensive and diabetic patients for blood pressure and glucose has been shown to be beneficial...
Autor:
Kong, A., Chiu, G., Shah, S.R., Bolodeoku, J., Casey, C.S., Massey, O., Patel, A., Black, C.M.
Publikováno v:
In Annals of Oncology September 2022 33 Supplement 7:S855-S855
Publikováno v:
The British Medical Journal, 1976 Apr 01. 1(6014), 880-880.
Externí odkaz:
https://www.jstor.org/stable/20409390
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chapple, Cr, Fianu Jonsson, A, Indig, M, Khullar, V, Rosa, J, Scarpa, Roberto Mario, Mistry, A, Wright, Dm, Bolodeoku, J, STAR Study Group
Publikováno v:
European urology. 52(4)
Objective To compare OAB symptom outcomes following initial randomised treatment with solifenacin 5mg or tolterodine ER 4mg at the 4-week clinic-visit and again at 12 weeks for patients choosing to remain on this treatment dose from 4 weeks. Methods
THrP je sekretorni protein uključen u mehanizam izazivanja hiperkalcemije vezane uz malignom, te molekula sa autokrinom i parakrinom ulogom u rastu i diferencijaciji stanice. U ovoj smo studiji istražili ekspresiju PTHrP mRNA koristeći RT-PCR tehn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::bb0a0733bc8d9717cb28e6a5d96c6eaf
https://www.bib.irb.hr/37685
https://www.bib.irb.hr/37685